How much funding has NewLimit raised?

NewLimit has raised $865.0M in total funding, most recently a Venture Round.

Who are NewLimit's investors?

NewLimit's investors include Kleiner Perkins, Founders Fund, Eli Lilly, Khosla Ventures, Human Capital, Duke University.

Where is NewLimit headquartered?

NewLimit is headquartered in South San Francisco, California, United States.

What industry is NewLimit in?

NewLimit operates in Biotech, Healthcare.

NewLimit

formerly New Limit

Extending human healthspan.

South San Francisco, United States · Founded 2022 · $865.0M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: newlimit.com
Total Funding: $865.0M
Last Round: $435.0M Venture RoundJun 2026
Rounds: 8

About

NewLimit is inventing medicines to restore youthful function in old cells by reprogramming the epigenome. We leverage technologies like single cell genomics, machine learning, and high-throughput functional assays to reveal epigenetic features of aging and discover rejuvenating interventions. Our first programs target the aging liver, immune, and vascular systems as stepping stones to significantly extending human healthspan.

Summary

NewLimit is a Biotech company based in South San Francisco, United States, founded in 2022. It has raised $865.0M in total across 8 rounds, most recently a $435.0M Venture Round round in Jun 2026. Investors include Kleiner Perkins, Founders Fund and Eli Lilly.

LinkedIn X (Twitter)GitHub